{"createdAt":"8/2/2020, 2:36:45 PM","timestamp":1596393405141,"Company ID number":"641","DMX_ISSUER_NAME":"Shijiazhuang Yiling Pharmaceutical Co., Ltd.","DMX_ISSUER_ID":"IID000000002623968","Country of Classification":"CHINA","name":"Shijiazhuang Yiling Pharmaceutical Co Ltd ","code":"002603","stock_exchange":"Shenzhen Stock Exchange","people":[{"id":"石家庄以岭药业股份有限公司_吴以岭","group":"board","name":"吴以岭","title":"董事长,董事","isMale":true,"age":"71","degree":"","salary":"102.4万","stockAmount":"-","description":"吴以岭先生,1949年出生,中国国籍,无境外居留权,中国工程院院士、络病研究与创新中药国家重点实验室主任、国家心血管病中心专家委员会副主任委员、中国医学科学院学部委员、国家中医药管理局络病重点研究室主任,担任中华中医药学会副会长、中国中西医结合学会副会长、中国医师协会副会长、世界中医药学会联合会副主席、中华中医药学会络病分会主任委员、石家庄以岭药业股份有限公司董事长。","lastUpdated":"2020-01-17"},{"id":"石家庄以岭药业股份有限公司_吴相君","group":"board","name":"吴相君","title":"董事","isMale":true,"age":"45","degree":"硕士","salary":"93.61万","stockAmount":"2.484亿","description":"吴相君先生,1975年出生,中国国籍,无境外居留权,中医专业硕士学位、英国格林威治大学工商管理硕士、副主任医师。自2005年起任公司营销中心总经理,2010年至2013年4月任公司常务副总经理兼营销中心总经理,2010年8月起任公司董事,2013年4月起任公司总经理。","lastUpdated":"2020-02-07"},{"id":"石家庄以岭药业股份有限公司_吴瑞","group":"board","name":"吴瑞","title":"董事","isMale":false,"age":"40","degree":"博士","salary":"70.87万","stockAmount":"2793万","description":"吴瑞女士,1980年出生,中国国籍,无境外居留权,国际商法专业,法学博士,历任以岭医药集团证券与投资事务部副经理。2010年8月起任石家庄以岭药业股份有限公司副总经理、董事会秘书。2016年12月起任石家庄以岭药业股份有限公司董事、董事会秘书。","lastUpdated":"2020-02-07"},{"id":"石家庄以岭药业股份有限公司_张秋莲","group":"board","name":"张秋莲","title":"董事","isMale":false,"age":"50","degree":"硕士","salary":"90.99万","stockAmount":"36.28万","description":"张秋莲女士,女,1970年出生,中国国籍,无境外居留权,学士学位,北京大学EMBA,1991年7月毕业于河北科技师范学院中兽医专业,中级经济师职称,中共党员。2006年10月至2012年12月,历任以岭药业营销中心部门经理、副总经理;2013年1月至2014年12月,任以岭药业公共事务部主任、营销中心副总经理兼以岭健康城科技有限公司总经理;2015年1月起任以岭药业公共事务中心主任、营销中心副总经理、以岭健康城科技有限公司总经理;2015年3月起任公司副总经理。2020年1月起任公司董事。","lastUpdated":"2020-02-07"},{"id":"石家庄以岭药业股份有限公司_李晨光","group":"board","name":"李晨光","title":"董事","isMale":true,"age":"47","degree":"硕士","salary":"71.85万","stockAmount":"-","description":"李晨光先生,1973年出生,中国国籍,无境外居留权,会计学专业,硕士学位。1994年10月至1996年12月,任职于石家庄开发区医药研究所附属医院;1997年至2009年任石家庄以岭药业股份有限公司营销中心财务部主任,2009年至2011年任公司财务部主任,2010年8月至2013年10月任公司董事;2018年4月起任公司董事、财务负责人。","lastUpdated":"2020-02-07"},{"id":"石家庄以岭药业股份有限公司_徐卫东","group":"board","name":"徐卫东","title":"董事","isMale":true,"age":"52","degree":"硕士","salary":"--","stockAmount":"27.68万","description":"徐卫东先生,1968年出生,中国国籍,无境外居留权,医学学士、工商管理硕士学位。1994年4月至2006年11月,在西安杨森制药有限公司任销售经理、销售培训经理;2006年12月至2008年4月,在北京诺华制药有限公司任培训经理。2008年5月加入石家庄以岭药业股份有限公司,2013年10月-2016年12月任公司董事,现任石家庄以岭药业股份有限公司人力资源中心主任。","lastUpdated":"2020-01-17"},{"id":"石家庄以岭药业股份有限公司_高沛勇","group":"board","name":"高沛勇","title":"独立董事","isMale":true,"age":"55","degree":"","salary":"--","stockAmount":"-","description":"高沛勇先生,1965年出生,中国国籍,无境外居留权,二级律师。河北政法职业学院法学系教师,曾任唐山路桥系破产重整管理人联席会主席、衡水百福房地产开发有限公司破产重整管理人联席会主席、藁城市果品公司破产清算案管理人联席会主席,河北高和化学破产清算案管理人联席会主席、邯郸执转破案管理人联席会主席、霸州利华系破产清算案管理人联席会主席、河北省石家庄三鹿集团股份有限公司破产管理人组长。现任河北省人民政府国有资产监督管理委员会、河北省国控、河北省教育厅、河北省体育局、中国黄金集团河北有限公司、河北省医科大学、石家庄市国资委等多家行政及企事业单位的常年法律顾问。","lastUpdated":"2020-01-17"},{"id":"石家庄以岭药业股份有限公司_王震","group":"board","name":"王震","title":"独立董事","isMale":true,"age":"47","degree":"博士","salary":"10.00万","stockAmount":"-","description":"王震,男,1973年9月出生,中共党员,河北地质大学会计学副教授,硕士研究生导师,在读博士,具有中国注册税务师、会计师资格。王震先生曾任河北经贸管理干部学院团委副书记、石家庄经济学院职业技术学院讲师,现任国家税务总局教育中心特聘专家、中国人民大学财政金融学院研究生合作导师、中南财经政法大学兼职硕士生导师、北京国家会计学院特聘客座教授、中国税收筹划研究会理事、中国商业会计学会理事,河北地质大学会计学院税收筹划研究中心主任。王震先生自2018年2月至今担任紫光学大独立董事。王震先生具有上市公司独立董事资格,现任河钢股份有限公司独立董事、石家庄以岭药业股份有限公司独立董事、中联联合投资集团(北京)有限公司独立董事。","lastUpdated":"2020-01-17"},{"id":"石家庄以岭药业股份有限公司_刘骁悍","group":"board","name":"刘骁悍","title":"独立董事","isMale":true,"age":"65","degree":"本科","salary":"--","stockAmount":"-","description":"刘骁悍,男,汉族,1955年8月生,中共党员,河北工业大学机械系精密仪器专业毕业,学士,高级工程师。曾任河北省医疗器械工业公司干部;河北省医药总公司医疗器械处主任科员、副处长;河北省医药管理局办公室主任、副局长(正处级)、党组成员;河北省药品监督管理局市场监督处处长、党组成员、助理巡视员;河北省食品药品监督管理局副局长、党组成员;河北省卫生厅党组成员,河北省食品药品监督管理局副局长、分党组成员;河北省卫生厅副厅长;河北省食品药品监督管理局巡视员。现任河北省医药行业协会党支部书记、华北制药股份有限公司独立董事。","lastUpdated":"2020-01-17"},{"id":"石家庄以岭药业股份有限公司_高学东","group":"supervisoryCommittee","name":"高学东","title":"监事会主席","isMale":true,"age":"50","degree":"本科","salary":"71.91万","stockAmount":"88.58万","description":"高学东先生,1970年出生,中国国籍,无境外居留权,中医专业,学士学位,主任中医师专业技术职称。1993年7月至2010年8月任河北以岭研究院副院长兼新药临床部主任;2010年8月起,任河北以岭医药研究院副院长兼新药临床部主任、公司监事,2014年8月起任监事会主席。","lastUpdated":"2020-01-17"},{"id":"石家庄以岭药业股份有限公司_刘根武","group":"supervisoryCommittee","name":"刘根武","title":"监事","isMale":true,"age":"47","degree":"中专","salary":"24.74万","stockAmount":"7700","description":"刘根武先生,1973年出生,中国国籍,无境外居留权,中专学历,民族传统体育专业。2002年起在以岭药业总经理办公室工作,2005年起任以岭药业秘书科副主任,2012年5月起至今任以岭药业后勤部主任,2014年8月起任公司监事。","lastUpdated":"2020-01-17"},{"id":"石家庄以岭药业股份有限公司_牛瑞华","group":"supervisoryCommittee","name":"牛瑞华","title":"职工监事","isMale":false,"age":"41","degree":"本科","salary":"28.73万","stockAmount":"-","description":"牛瑞华女士,1979年出生,中国国籍,无境外居留权,中药专业,本科学历。2000年7月至2006年9月,以岭医药集团秘书科工作;2006年9月至2008年5月,担任河北以岭医院办公室主任;2008年5月至2009年2月,任以岭医药集团总经理办公室副主任兼秘书科主任;2009年3月至2010年8月,任石家庄以岭药业股份有限公司办公室主任;2010年8月起,任公司监事。","lastUpdated":"2019-12-21"},{"id":"石家庄以岭药业股份有限公司_吴相君","group":"manager","name":"吴相君","title":"总经理","isMale":true,"age":"45","degree":"硕士","salary":"93.61万","stockAmount":"2.484亿","description":"吴相君先生,1975年出生,中国国籍,无境外居留权,中医专业硕士学位、英国格林威治大学工商管理硕士、副主任医师。自2005年起任公司营销中心总经理,2010年至2013年4月任公司常务副总经理兼营销中心总经理,2010年8月起任公司董事,2013年4月起任公司总经理。","lastUpdated":"2020-02-07"},{"id":"石家庄以岭药业股份有限公司_吴瑞","group":"manager","name":"吴瑞","title":"董事会秘书","isMale":false,"age":"40","degree":"博士","salary":"70.87万","stockAmount":"2793万","description":"吴瑞女士,1980年出生,中国国籍,无境外居留权,国际商法专业,法学博士,历任以岭医药集团证券与投资事务部副经理。2010年8月起任石家庄以岭药业股份有限公司副总经理、董事会秘书。2016年12月起任石家庄以岭药业股份有限公司董事、董事会秘书。","lastUpdated":"2020-02-07"},{"id":"石家庄以岭药业股份有限公司_张秋莲","group":"manager","name":"张秋莲","title":"副总经理","isMale":false,"age":"50","degree":"硕士","salary":"90.99万","stockAmount":"36.28万","description":"张秋莲女士,女,1970年出生,中国国籍,无境外居留权,学士学位,北京大学EMBA,1991年7月毕业于河北科技师范学院中兽医专业,中级经济师职称,中共党员。2006年10月至2012年12月,历任以岭药业营销中心部门经理、副总经理;2013年1月至2014年12月,任以岭药业公共事务部主任、营销中心副总经理兼以岭健康城科技有限公司总经理;2015年1月起任以岭药业公共事务中心主任、营销中心副总经理、以岭健康城科技有限公司总经理;2015年3月起任公司副总经理。2020年1月起任公司董事。","lastUpdated":"2020-02-07"},{"id":"石家庄以岭药业股份有限公司_赵韶华","group":"manager","name":"赵韶华","title":"副总经理","isMale":true,"age":"54","degree":"本科","salary":"86.85万","stockAmount":"59.05万","description":"赵韶华先生,1966年出生,中国国籍,无境外居留权,学士学位,正高级工程师。赵韶华先生自1989年起即从事科研与制药管理,1994年起任河北以岭医药研究院常务副院长、公司技术总监。2012年2月至今任石家庄以岭药业股份有限公司副总经理。2017年8月至2020年1月任公司董事。","lastUpdated":"2020-02-07"},{"id":"石家庄以岭药业股份有限公司_韩月芝","group":"manager","name":"韩月芝","title":"副总经理","isMale":false,"age":"54","degree":"本科","salary":"68.46万","stockAmount":"88.2万","description":"韩月芝女士,1966年出生,中国国籍,无境外居留权,药学本科,高级工程师。1992年11月至今,历任石家庄以岭药业股份有限公司车间主任、生产科长、生产副总经理助理、质量总监。现任石家庄以岭药业股份有限公司生产管委会主任。2016年12月起任公司副总经理。","lastUpdated":"2020-02-07"},{"id":"石家庄以岭药业股份有限公司_王蔚","group":"manager","name":"王蔚","title":"副总经理","isMale":false,"age":"50","degree":"硕士","salary":"80.13万","stockAmount":"143.6万","description":"王蔚女士,1970年出生,中国国籍,无境外居留权,研究生学历,高级经济师。1997年至2010年,历任河北以岭医药集团有限公司人事部主任、人力资源部副主任兼培训部主任、总裁办公室主任。2011年至今,任石家庄以岭药业股份有限公司行政部主任。2016年12月起任公司副总经理。","lastUpdated":"2020-02-07"},{"id":"石家庄以岭药业股份有限公司_张科源","group":"manager","name":"张科源","title":"副总经理","isMale":true,"age":"53","degree":"本科","salary":"112.8万","stockAmount":"-","description":"张科源先生,男,1967年出生,中国国籍,无境外居留权,学士学位,1990年9月毕业于河北中医学院中医专业,副主任医师,营销师。2001年至今,历任石家庄以岭药业股份有限公司销售部经理、营销中心副总经理。2019年10月起任公司副总经理。","lastUpdated":"2020-02-07"},{"id":"石家庄以岭药业股份有限公司_纪珍强","group":"manager","name":"纪珍强","title":"副总经理","isMale":true,"age":"48","degree":"本科","salary":"--","stockAmount":"-","description":"纪珍强先生,男,1972年出生,中国国籍,无境外居留权,学士学位,1996年7月毕业于河北工业大学工业管理专业。1997年至今,历任石家庄以岭药业股份有限公司销售经理、人力资源经理、商务总监、营销中心副总经理。","lastUpdated":"2020-02-07"},{"id":"石家庄以岭药业股份有限公司_李晨光","group":"manager","name":"李晨光","title":"财务负责人","isMale":true,"age":"47","degree":"硕士","salary":"71.85万","stockAmount":"-","description":"李晨光先生,1973年出生,中国国籍,无境外居留权,会计学专业,硕士学位。1994年10月至1996年12月,任职于石家庄开发区医药研究所附属医院;1997年至2009年任石家庄以岭药业股份有限公司营销中心财务部主任,2009年至2011年任公司财务部主任,2010年8月至2013年10月任公司董事;2018年4月起任公司董事、财务负责人。","lastUpdated":"2020-02-07"}],"companyName":"石家庄以岭药业股份有限公司","province":"河北省","englishName":"Shijiazhuang Yiling Pharmaceutical","industry":"医药生物 — 中药Ⅱ","website":"www.yiling.cn","mainBusiness":"致力于中成药的研发、生产与销售","productsName":["通心络胶囊","参松养心胶囊","连花清瘟胶囊","芪苈强心胶囊"],"actualController":"吴以岭、吴相君、吴瑞","actualControllerSharePercentage":"31.26、20.63、2.32%","registeredCapital":"12.04亿元","employeeAmount":"9618","phone":"86-0311-85901311","location":"河北省石家庄市裕华区高新技术产业开发区天山大街238号","chineseDescription":"石家庄以岭药业股份有限公司是一家主要致力于中成药的研发、生产与销售的企业.公司拥有通过GMP认证的胶囊、片剂、颗粒剂、针剂生产线,以及通过欧盟认证的化学药制剂车间.公司是国家高新技术企业,凭借强大的研发力,多次承担国家\"973\"、\"863\"专项和国家科技攻关、支撑及生物医药重大专项等国家及省部级重大项目,获科技奖励20余项,已经获得授权的国内发明专利及实用新型专利29项、国际发明专利2项、已授权外观设计专利17项。","foundedDate":"1994-05-06","goPublicDate":"2011-07-28","companyHistory":"","shareholders":[{"organizationId":"T000162110","holderName":"以岭医药科技有限公司","totalShare":"3.76亿","sharePercentage":"31.26%"},{"organizationId":"","holderName":"吴相君","totalShare":"2.48亿","sharePercentage":"20.63%"},{"organizationId":"","holderName":"田书彦","totalShare":"6896.62万","sharePercentage":"5.73%"},{"organizationId":"","holderName":"吴瑞","totalShare":"2792.57万","sharePercentage":"2.32%"},{"organizationId":"T000832333","holderName":"广东省铁路发展基金有限责任公司","totalShare":"1710.53万","sharePercentage":"1.42%"},{"organizationId":"T000293644","holderName":"青岛国信资本投资有限公司","totalShare":"1329.43万","sharePercentage":"1.10%"},{"organizationId":"T000138941","holderName":"青岛海尔创业投资有限责任公司","totalShare":"1144.16万","sharePercentage":"0.95%"},{"organizationId":"T000125370","holderName":"香港中央结算有限公司","totalShare":"844.01万","sharePercentage":"0.70%"},{"organizationId":"","holderName":"吴以红","totalShare":"744.00万","sharePercentage":"0.62%"},{"organizationId":"","holderName":"林清","totalShare":"721.43万","sharePercentage":"0.60%"}],"englishDescription":" SHIJIAZHUANG YILING PHARMACEUTICAL CO., LTD is a China-based company, principally engaged in the research and development, manufacture and distribution of pharmaceuticals. The Company mainly provides cardiovascular and cerebrovascular drugs and anti-cold drugs. The Company also provides food and beverage products. The Company distributes its products within domestic market and to overseas markets.","englishIndustry":"Major Drugs","Price to earnings (ttm)":"50.73","Price to sales (ttm)":"5.80","Price to book (mrq)":"4.57","Price to cash flow (ttm)":"--","Total debt to equity (mrq)":"1.07","Lt debt to equity (mrq)":"0.00","Return on investment (ttm)":"9.00","Return on equity (ttm)":"8.07","Income statement":{"Revenue":"5,825.29","Total revenue":"5,825.29","Cost of revenue, total":"2,106.21","Gross profit":"3,719.08","Selling/general/admin. expenses, total":"2,565.71","Research & development":"363.83","Depreciation/amortization":"140.98","Interest exp.(inc.),net-operating, total":"(24.74)","Unusual expense (income)":"(7.40)","Other operating expenses, total":"(29.46)","Total operating expense":"5,115.12","Operating income":"710.18","Gain (loss) on sale of assets":"(1.25)","Other, net":"(1.04)","Net income before taxes":"707.89","Provision for income taxes":"104.84","Net income after taxes":"603.04","Minority interest":"3.46","Net income before extra. items":"606.50","Net income":"606.50","Income available to com excl extraord":"606.50","Income available to com incl extraord":"606.50","Diluted net income":"606.50","Diluted weighted average shares":"1,203.72","Diluted eps excluding extraord items":"0.50","Dps - common stock primary issue":"0.20","Diluted normalized eps":"0.50"},"Balance sheet":{"Cash":"1.14","Cash & equivalents":"712.28","Short term investments":"292.73","Cash and short term investments":"1,006.14","Accounts receivable - trade, net":"1,117.12","Total receivables, net":"2,466.09","Total inventory":"1,221.81","Prepaid expenses":"354.15","Other current assets, total":"20.00","Total current assets":"5,068.20","Property/plant/equipment, total - gross":"4,507.91","Accumulated depreciation, total":"(1,356.50)","Property/plant/equipment, total - net":"3,151.41","Intangibles, net":"754.39","Long term investments":"17.18","Other long term assets, total":"78.22","Total assets":"9,069.40","Accounts payable":"506.77","Accrued expenses":"147.44","Notes payable/short term debt":"50.05","Other current liabilities, total":"102.18","Total current liabilities":"806.43","Long term debt":"0.00","Total long term debt":"0.00","Total debt":"50.05","Minority interest":"8.13","Other liabilities, total":"310.42","Total liabilities":"1,124.98","Common stock, total":"1,203.72","Additional paid-in capital":"2,931.92","Retained earnings (accumulated deficit)":"3,934.80","Treasury stock - common":"(122.15)","Other equity, total":"(3.87)","Total equity":"7,944.41","Total liabilities & shareholders' equity":"9,069.40","Total common shares outstanding":"1,203.72","Tangible book value per share, common eq":"5.97","Goodwill, net":"0.00"},"Cash flow":{"Cash receipts":"5,272.25","Cash payments":"(1,746.35)","Cash taxes paid":"(727.90)","Changes in working capital":"(2,729.07)","Cash from operating activities":"68.93","Capital expenditures":"(454.43)","Other investing cash flow items, total":"491.55","Cash from investing activities":"37.12","Financing cash flow items":"(99.79)","Total cash dividends paid":"(119.80)","Issuance (retirement) of debt, net":"50.00","Cash from financing activities":"(169.59)","Foreign exchange effects":"(0.64)","Net change in cash":"(64.18)"},"keyMetrics":{"Price and Volume":{"Price closing or last bid":"31.84","52 Week High":"41.69","52 Week Low":"10.01","Pricing date":"","10 Day Average Trading Volume":"35.28","Market Capitalization":"38,326.36","52 Week High Date":"","52 Week Low Date":"","3 Month Average Trading Volume":"1,100.89","Beta":"0.85","1 Day Price Change":"-0.78","13 Week Price Return (Daily)":"10.63","26 Week Price Return (Daily)":"96.18","5 Day Price Return (Daily)":"9.49","52 Week Price Return (Daily)":"198.41","Year To Date Price Return (Daily)":"156.15","Month to Date Price Return (Daily)":"2.08","Price Relative to S&P500 (4 Week)":"-6.66","Price Relative to S&P500 (13 Week)":"-13.02","Price Relative to S&P500 (26 Week)":"53.66","Price Relative to S&P500 (52 Week)":"102.79","Price Relative to S&P500 (YTD)":"95.92"},"Per Share Data":{"EPS excl. Extra Items (Annual)":"0.50","EPS excl. Extra Items (TTM)":"0.63","EPS Normalized (Annual)":"0.50","Revenue per Share (Annual)":"4.84","Revenue per Share (TTM)":"5.48","Book Value (Per Share Annual)":"6.60","Book Value (Per Share Quarterly)":"6.96","Tangible Book Value (Per Share Annual)":"5.97","Tangible Book Value (Per Share Quarterly)":"6.33","Cash Per Share (Per Share Annual)":"0.84","Cash Per Share (Per Share Quarterly)":"1.89","Cash Flow (Per Share Annual)":"0.72","Cash Flow (Per Share TTM)":"--","Dividend (Per Share Annual)":"0.20","Dividends (Per Share TTM)":"0.20","EBITD (Per Share TTM)":"0.71","EPS Basic excl. Extra Items (Annual)":"0.50","EPS Basic excl. Extra Items (TTM)":"0.63","EPS incl. Extra Items (Annual)":"0.50","EPS incl. Extra Items (TTM)":"0.63","Free Cash Flow (Per Share TTM)":"0.42","Dividend (Per Share 5Y)":"0.12"},"Valuation":{"P/E excl. Extra Items (Annual)":"63.19","P/E excl. Extra Items (TTM)":"50.73","P/E Normalized (Annual)":"63.74","Price to sales (Annual)":"6.58","Price to sales (TTM)":"5.80","Price to Tangible Book (Annual)":"5.33","Price to Tangible Book (Quarterly)":"5.03","Price to Free Cash Flow (Per Share Annual)":"--","Price to Cash Flow (Per Share TTM)":"--","Price to Free Cash Flow (Per Share TTM)":"75.75","Price to Book (Annual)":"4.82","Price to Book (Quarterly)":"4.57","P/E Basic excl. Extra Items (TTM)":"35.77","P/E excl. Extra Items High (TTM)":"60.39","P/E excl. Extra Items Low (TTM)":"21.05","P/E incl. Extra Items (TTM)":"50.73","Net Debt (Interim)":"-2,186.73","Net Debt (Annual)":"-956.09","Dividend Yield (5Y)":"0.81","Dividend Yield":"0.63","Current Dividend Yield (TTM)":"0.63"},"Financial Strength":{"Free Cash Flow (Annual)":"-505.30","Current Ratio (Annual)":"6.28","Net Interest coverage (Annual)":"--","Long Term Debt/Equity (Annual)":"0.00","Payout Ratio (Annual)":"39.35","Quick Ratio (Annual)":"4.77","Total Debt/Total Equity (Annual)":"0.63","Current EV/Free Cash Flow (Annual)":"129.99","Current EV/Free Cash Flow (TTM)":"--","Current Ratio (Quarterly)":"5.14","Long Term Debt/Equity (Quarterly)":"0.00","Quick Ratio (Quarterly)":"3.92","Total Debt/Total Equity (Quarterly)":"1.07","Free Cash Flow (TTM)":"505.95","Net Interest Coverage (TTM)":"--","Payout Ratio (TTM)":"31.57"},"Margins":{"Gross Margin (Annual)":"63.84","Gross Margin (TTM)":"62.51","Net Profit Margin % (Annual)":"10.35","Net Profit Margin (TTM)":"11.39","Operating Margin (Annual)":"12.19","Operating Margin (TTM)":"13.45","Pretax Margin (TTM)":"13.38","Pretax Margin (Annual)":"12.15","Operating Margin (5Y)":"14.66","Pretax Margin (5Y)":"14.59","Free Operating Cash Flow/Revenue (5Y)":"-5.21","Free Operating Cash Flow/Revenue (TTM)":"7.66","Gross Margin (5Y)":"65.58","Net Profit Margin (5Y)":"12.34"},"Management Effectiveness":{"Return on Assets (Annual)":"6.84","Return on Equity (TTM)":"8.07","Return on Average Equity (Annual)":"7.82","Return on Average equity (TTM)":"9.35","Return on Investment (Annual)":"7.52","Return on Investment (TTM)":"9.00","Return on Average Assets (5Y)":"7.57","Return on Average Equity (5Y)":"8.74","Return on Investment (5Y)":"8.40","Asset Turnover (Annual)":"0.66","Asset Turnover (TTM)":"0.71","Inventory Turnover (Annual)":"1.76","Inventory Turnover (TTM)":"1.90","Net Income/Employee (Annual)":"81,294.65","Net Income/Employee (TTM)":"78,257.90","Receivables Turnover (Annual)":"6.71","Receivables Turnover (TTM)":"6.25","Revenue/Employee (Annual)":"785,291.80","Revenue/Employee (TTM)":"687,147.80"},"Growth":{"Revenue Growth (Quarterly YoY)":"50.56","Revenue Growth Rate (5Y)":"14.80","EPS Growth (Quarterly YoY)":"52.21","EPS Growth (TTM YoY)":"31.24","EPS Growth Rate (5Y)":"9.88","Dividend Growth Rate (3Y)":"25.99","Revenue Growth (TTM YoY)":"38.15","Revenue Growth (Per Share 5Y)":"13.30","Revenue Growth Rate (3Y)":"14.81","EPS Growth Rate (3Y)":"2.21","Book Value Growth Rate (Per Share 5Y)":"10.98","Tangible Book Value Total Equity CAGR (5Y)":"12.23","Capital Spending growth rate 5 year":"0.19","EBITDA CAGR (5Y)":"14.93","EBITDA Interim CAGR (5Y)":"15.27","Free Operating Cash Flow CAGR (5Y)":"--","Total Debt CAGR (5Y)":"--","Net Profit Margin Growth Rate (5Y)":"-3.13"},"Income Statement":{"Revenue (Annual)":"5,825.29","Revenue (TTM)":"6,608.99","EBITD (Annual)":"936.77","EBITD (TTM)":"859.53","Earnings Before Taxes (Annual)":"707.89","Earnings Before Taxes (TTM)":"884.47","Net Income to Common (Annual)":"606.50","Net Income to Common (TTM)":"756.11","Earnings Before Taxes Normalized (Annual)":"701.73","Net Income Available to Common Normalized (Annual)":"601.26","Diluted Normalized EPS excl. Extra Items (TTM)":"0.63"}}}